# Adam Kinsey

> Adam Kinsey is the San Diego-based co-founder and chief executive of Ventrix, a biotechnology company translating UC San Diego biomaterials research into catheter-deliverable products. A biomedical engineer with a joint UC Berkeley-UCSF Ph.D., a Haas management certificate and experience in biotechnology intellectual-property strategy, Kinsey has spent his career working where science, patents, funding and clinical development meet.

- **Role:** Chief Executive Officer and Co-Founder at Ventrix
- **Organizations:** Ventrix, Wilson Sonsini Goodrich & Rosati
- **Education:** B.S. in Biomedical Engineering, Johns Hopkins University, Ph.D. in Bioengineering, University of California, Berkeley and University of California, San Francisco, Certificate in Management of Technology, Haas School of Business, University of California, Berkeley
- **Known for:** Co-founded Ventrix and built the company around biomaterials technology licensed from UC San Diego., Served as principal investigator on multiple federal SBIR projects spanning preclinical development, a first-in-human program and an infusible formulation., Co-authored the 2019 first-in-human VentriGel study published in JACC: Basic to Translational Science.

## Career timeline

- **2007-2010** — Worked as a patent agent at Wilson Sonsini Goodrich & Rosati, focusing on intellectual-property strategy for young companies and venture investors.
- **2009-2010** — Co-founded Ventrix and became its chief executive; California records list the company as filed in April 2009, while public career records date his CEO tenure from 2010.
- **2011** — Named principal investigator and business contact on a federal SBIR award for a catheter-deliverable regenerative biomaterial project.
- **2011** — Selected as a finalist in the fifth annual San Diego Tech Coast Angels Quick Pitch competition.
- **2012** — Ventrix closed a Series A financing round; Kinsey also appeared as a co-author on published preclinical biomaterial research.
- **2016** — Named principal investigator on a $1,026,130 NIH Phase IIB SBIR award supporting a first-in-human study.
- **2019** — Co-authored the published first-in-human study of the VentriGel cardiac extracellular-matrix hydrogel.
- **2020** — Named principal investigator on a federal SBIR project for an intracoronary-infusible version of the biomaterial.
- **2023** — Named principal investigator on a $1,992,340 NIH Phase II SBIR award for pivotal preclinical studies of an infusible extracellular-matrix formulation.
- **2025** — Ventrix remained listed as an active California business, with Kinsey recorded as chief executive.

## Achievements

- Co-founded Ventrix and built the company around biomaterials technology licensed from UC San Diego.
- Served as principal investigator on multiple federal SBIR projects spanning preclinical development, a first-in-human program and an infusible formulation.
- Co-authored the 2019 first-in-human VentriGel study published in JACC: Basic to Translational Science.
- Reached the finals of the 2011 San Diego Tech Coast Angels Quick Pitch competition.
- Combined doctoral bioengineering training with intellectual-property and technology-management experience in a biotechnology operating role.

## Latest updates

- **2025-07** — A California business-record aggregation based on the Secretary of State registry listed Ventrix as active and Kinsey as chief executive.
- **2023-09** — A $1,992,340 NIH Phase II SBIR award began for pivotal preclinical work on Ventrix's infusible extracellular-matrix formulation, with Kinsey as principal investigator.

## Links

- Website: https://ventrixbio.com
- LinkedIn: https://www.linkedin.com/in/adam-kinsey-43b72a19
- Twitter/X: https://twitter.com/ventrixheart
- Facebook: https://facebook.com/ventrixheart

---

Profile page: https://yespress.io/adam-kinsey
Published by YesPress — https://yespress.io
Last updated: 2026-08-27